TOVX (Theriva Biologics) Research & Development: $5.99 Mil (TTM As of Mar. 2026)


TOVX Theriva Biologics Inc TOVX
28 GF Score
Price $0.24
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Research & Development?

Theriva Biologics TOVX +0.29% 28 Research & Development is $5.99 Mil as of Mar. 2026. GuruFocus rates TOVX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Theriva Biologics's Research & Development for the three months ended in Mar. 2026 was $0.36 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $5.99 Mil.

Theriva Biologics  (AMEX:TOVX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Theriva Biologics Research & Development Related Terms

Theriva Biologics Research & Development Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Research & Development Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.80 11.72 14.31 12.03 8.60

Theriva Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 1.95 2.55 1.13 0.36
TOVX
28GF Score
Theriva Biologics Inc TOVX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $5.99 Mil mean?
Theriva Biologics (TOVX) has a Research & Development of $5.99 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Theriva Biologics and its competitors.
Is Theriva Biologics' Research & Development too high?
Theriva Biologics' current Research & Development is $5.99 Mil. Overall, Theriva Biologics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Research & Development compare to CALC and PHIO?
Theriva Biologics' Research & Development of $5.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Theriva Biologics and its competitors. Theriva Biologics's current Research & Development is $5.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current Research & Development of $5.99 Mil. The current Research & Development is $5.99 Mil. Theriva Biologics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current Research & Development is $5.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
28GF Score

Get the complete analysis for TOVX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price